Financing

#DNA #Financing #Funding #Investment #Synthetic biology

$24 million funding to accelerate synthetic biology research

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development… Read More

#Business & Investment #News

T cells attack a cancer cell
#Financing #Grey Wolf Therapeutics #Immuno-oncology #Investment #Oncology #T cell activation

$49 million raised to fund original immuno-oncology approach

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance… Read More

#Business & Investment #News #Start-up Zone

Preterm infant in the neonatal unit
#Brain #Financing #Neonatal #Neurodevelopmental disorders #Paediatrics #Start-ups #Tellus Therapeutics

Neonatal therapeutics company raises $35 million

Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.   The capital will be used to continue preclinical work conducted through the seed… Read More

#News #Start-up Zone

#Biologics / Biotechnology #Cancer research #Financing #Investment #Oncology #RNA

Biotech company raises $30M to target RNA modifying enzymes

Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round.  The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases.  The financing was co-led by existing investors M Ventures,… Read More

#Business & Investment #News

Pedro Correa de Sampaio and Annelise Soulier
#Cancer immunotherapy #Cancer research #Financing #Start-ups

Start-up raises £520K to improve immunotherapy outcomes

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More

#News #Start-up Zone

Using C. elegans to screen compounds
#C elegans #Drug screening #Drug toxicity #Financing #Investment #Research services

Anti-ageing research company secures investment

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by… Read More

#Business & Investment #News

#Biotechnology #Disease networks #Drug targets #Financing #Investment #Precision medicine #Start-ups

New biotech aspires to reveal insights into disease biology

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative… Read More

#News #Start-up Zone